Vaxcell-Bio Therapeutics
Vaxcell-Bio develops Vax-NK/Vax-CAR cancer immunotherapies, veterinary drug Baxrukin-15, and pet supplements Goldmune and Bakshure.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureVaxcell-Bio Therapeutics was founded in 2010 and listed on KOSDAQ in 2020 as a cancer immunotherapy developer. Its pipeline includes the Vax-NK natural killer cell therapy platform, the Vax-CAR platform (CAR-MIL, CAR-T), the veterinary immunotherapy Baxrukin-15, and the pet health supplements Goldmune and Bakshure. The company completed a Phase 2a trial of Vax-NK in advanced hepatocellular carcinoma and submitted a closing report to the Ministry of Food and Drug Safety, while Baxrukin-15 is sold domestically through Yuhan Corporation and supplied overseas under agreements with VisionMed and Nubepharma.
Products & technology
- Vax-NK cancer immune cell therapyNK-cell-based cancer immunotherapy; Phase 2a completed in advanced hepatocellular carcinoma
- Vax-CAR (CAR-MIL, CAR-T)CAR-MIL for multiple myeloma and dual-antigen-targeting CAR-T for solid tumors, preclinical
- CAR-NK therapyFor autoimmune disease, co-developed with BioDesignLab and Samsung Medical Center
- Small-molecule targeted anticancer agent (MYO1D)First-in-class agent degrading MYO1D to degrade growth factor receptors
- Bispecific antibody therapy (nanobody)Nanobody-based bispecific antibody for solid tumors
- Baxrukin-15Veterinary prescription drug for post-surgical mammary tumor immunotherapy and combination therapy for canine lymphoma
- GoldmunePet immune supplement containing fucoidan, Sparassis crispa, and goat milk
- BakshureNew immune supplement containing beta-glucan
Clinical trials
data.go.kr5 MFDS clinical trial authorisations · 2013–2019 (Phase 2a 2 · Phase 1 2 · Phase 2 1)
- Phase 2aVax-DC/MM2019-04-05
1 trial site
- Phase 2aVax-NK/HCC2018-05-30
5 trial sites
- Phase 2Vax-DC/MM2017-08-14
1 trial site
- Phase 1Vax-NK/HCC2016-01-12
1 trial site
- Phase 1Vax-DC/MM2013-10-16
1 trial site
R&D and key agreements
Source: DART corporate disclosureVax-NK · 진행성 간세포암 · 임상 2a상 완료 · Closing report submitted to Ministry of Food and Drug Safety
Vax-NK · 소세포폐암(확장병기) · 첨단재생의료 임상연구 · Subject enrollment completed November 2025; results report in progress
Vax-NK · 췌장암 · 첨단재생의료 임상연구 · Clinical study initiated July 2025, ongoing
CAR-MIL · 다발골수종 · 전임상
CAR-T · 고형암 · 전임상 · Dual-antigen targeting
CAR-NK · 자가면역질환 · Co-developed with BioDesignLab and Samsung Medical Center
저분자화합물 표적항암제(MYO1D) · First-in-class development degrading growth factor receptors via MYO1D degradation
이중항체 치료제 · 고형암 · 개발 중 · Nanobody structure
DDS/제제 플랫폼 · 황반변성 등 · Platform acquired via merger with AL Biotech; completed formulations licensed to pharmaceutical companies
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer2
- PerplexityPerplexityBot2
Measured since Aug 25, 2026 · 2 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition